Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone949-396-6322
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$710,000.00
Profitability
Miscellaneous
Employees87
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable
Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions
What is Axonics Modulation Technologies' stock symbol?
Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."
How were Axonics Modulation Technologies' earnings last quarter?
Axonics Modulation Technologies Inc (NASDAQ:AXNX) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.14. The firm earned $1.31 million during the quarter, compared to analyst estimates of $1.45 million. Axonics Modulation Technologies had a negative return on equity of 55.57% and a negative net margin of 1,530.43%. The company's revenue for the quarter was up 555.0% on a year-over-year basis. View Axonics Modulation Technologies' Earnings History.
When is Axonics Modulation Technologies' next earnings date?
What guidance has Axonics Modulation Technologies issued on next quarter's earnings?
Axonics Modulation Technologies issued an update on its fourth quarter 2019
Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10-10 million, compared to the consensus revenue estimate of $4.24 million.
What price target have analysts set for AXNX?
8 brokerages have issued 12 month price targets for Axonics Modulation Technologies' shares. Their forecasts range from $38.00 to $48.00. On average, they expect Axonics Modulation Technologies' share price to reach $43.13 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price. View Analyst Price Targets for Axonics Modulation Technologies.
What is the consensus analysts' recommendation for Axonics Modulation Technologies?
Has Axonics Modulation Technologies been receiving favorable news coverage?
Headlines about AXNX stock have trended somewhat positive recently, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axonics Modulation Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Axonics Modulation Technologies.
Are investors shorting Axonics Modulation Technologies?
Axonics Modulation Technologies saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 5,340,000 shares, an increase of 11.9% from the December 31st total of 4,770,000 shares. Based on an average daily trading volume, of 680,700 shares, the days-to-cover ratio is presently 7.8 days. Currently, 34.5% of the shares of the stock are short sold. View Axonics Modulation Technologies' Current Options Chain.
Who are some of Axonics Modulation Technologies' key competitors?
Some companies that are related to Axonics Modulation Technologies include Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Cardiovascular Systems (CSII), AtriCure (ATRC), Atrion (ATRI), Silk Road Medical (SILK), Shockwave Medical (SWAV), Cryolife (CRY), Tactile Systems Technology (TCMD), Luminex (LMNX), Orthofix Medical (OFIX) and Orthopediatrics (KIDS).
What other stocks do shareholders of Axonics Modulation Technologies own?
Who are Axonics Modulation Technologies' key executives?
Axonics Modulation Technologies' management team includes the folowing people:
- Mr. Raymond W. Cohen, CEO & Director (Age 60)
- Mr. Danny L. Dearen, Pres & CFO (Age 56)
- Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 56)
- Mr. Rinda K. Sama, Chief Operating Officer (Age 40)
- Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 46)
When did Axonics Modulation Technologies IPO?
(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Axonics Modulation Technologies' major shareholders?
Axonics Modulation Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (2.14%), Rhenman & Partners Asset Management AB (1.15%), California Public Employees Retirement System (0.10%) and Valeo Financial Advisors LLC (0.01%). Company insiders that own Axonics Modulation Technologies stock include Andera Partners, Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Danny L Dearen, Geoff Pardo, Healthcare Holding BV Gilde, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama. View Institutional Ownership Trends for Axonics Modulation Technologies.
Which institutional investors are buying Axonics Modulation Technologies stock?
AXNX stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, California Public Employees Retirement System and Valeo Financial Advisors LLC. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Healthcare Holding BV Gilde, Nancy Lynn Md Snyderman and Raymond W Cohen. View Insider Buying and Selling for Axonics Modulation Technologies.
How do I buy shares of Axonics Modulation Technologies?
Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Axonics Modulation Technologies' stock price today?
One share of AXNX stock can currently be purchased for approximately $30.77.
How big of a company is Axonics Modulation Technologies?
Axonics Modulation Technologies has a market capitalization of $880.02 million and generates $710,000.00 in revenue each year. The company earns $-32,480,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Axonics Modulation Technologies employs 87 workers across the globe.View Additional Information About Axonics Modulation Technologies.
What is Axonics Modulation Technologies' official website?
How can I contact Axonics Modulation Technologies?
Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322.
MarketBeat Community Rating for Axonics Modulation Technologies (NASDAQ AXNX)
MarketBeat's community ratings are surveys of what our community members think about Axonics Modulation Technologies and other stocks. Vote "Outperform" if you believe AXNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
